The Information Asymmetry Problem in Biopharma Boards
The Information Asymmetry Problem in Biopharma Boards
In every other industry, a competent board can independently verify the substance of what they are being told.
A consumer products board can read the customer research, look at the sales numbers, walk a store, and form an independent view of whether the brand is healthy. A software company board can use the product, look at the engagement metrics, talk to customers, and develop a defensible point of view on whether the strategy is working. A manufacturing board can tour the factory, study the operational metrics, and reason from first principles about whether the operation is well run. In each of these cases, a director who does the work can verify the substance of what management is presenting and form an independent judgment about it.
A biopharma board cannot, in most cases, do this.
The chemistry, biology, statistics, and regulatory mechanics that determine whether a drug works, whether a trial succeeded, whether a safety signal is meaningful, or whether the FDA is going to grant approval are technical enough that only a few people on most boards can verify the substance of what they are being told. The Chief Medical Officer presents the trial results; most directors have to trust the interpretation. The Chief Scientific Officer explains the mechanism; most directors are not in a position to challenge it. The regulatory affairs lead reports on the FDA interaction; most directors cannot independently assess what the agency was actually signaling.
This is the information asymmetry problem. It is the structural condition that makes biopharma governance distinctively hard, and it does not go away no matter how diligent the board is. The question is not whether you can eliminate the asymmetry. You cannot. The question is whether the board has built the structural protections that mean it does not have to.
This article works through the shape of the asymmetry, the common failure modes in how boards respond to it, and the governance disciplines that allow a board to function well despite a condition that cannot be solved.
The Three Faces of the Asymmetry
The information asymmetry in biopharma governance shows up in three distinct domains, and the board's relationship to each is different.
The first is scientific. Whether the molecule does what the company says it does — whether the mechanism is what is claimed, whether the preclinical evidence is robust, whether the platform extends to the indications management is talking about — is a domain in which most directors cannot independently form a view. They are entirely dependent on the Chief Scientific Officer, the scientific advisory board, and whatever third-party validation the company has accumulated. The asymmetry here is most extreme: the directors are not just unable to verify the science; in many cases they are unable to formulate the right questions to ask about it.
The second is clinical and medical. Whether a trial was designed appropriately, whether the dosing decisions were sound, whether a safety signal is meaningful or noise, whether the patient population was chosen well — these are decisions where the asymmetry is meaningful but typically less extreme than the scientific case. A board that includes a former CMO, a clinical investigator, or a physician with relevant therapeutic experience has at least one director who can engage substantively. But even on such boards, the remaining directors are often dependent on that one voice, which creates its own concentration risk.
The third is regulatory. Whether the FDA's response to a Type B meeting indicates a favorable disposition or polite skepticism, whether a Complete Response Letter is fixable or fatal, whether an Advisory Committee outcome is likely to be a yes or a maybe — these are reads that require deep experience with regulatory dynamics. Few directors have that experience. The board is largely dependent on the regulatory affairs lead, the outside regulatory counsel, and whatever pattern recognition can be drawn from advisors who have been through similar situations before.
These three asymmetries compound. The scientific story shapes the clinical strategy; the clinical strategy shapes the regulatory interactions; the regulatory interactions feed back into how the company explains the science to investors and to itself. A board that cannot verify at the scientific level often cannot evaluate whether the clinical and regulatory choices that follow from it are sound. The asymmetry runs through the entire chain of decisions, not just at any one point.
How Boards Typically Respond Badly
There are four common patterns of failure in how boards handle the asymmetry, and most clinical-stage biopharma boards exhibit at least one of them.
The first is deference. The board, recognizing that it cannot verify what the CMO and CSO are saying, defaults to trusting them on the substance of every clinical and scientific question. This is the most common pattern and the most dangerous. It produces the boards that are most surprised when a trial fails for reasons that were knowable in advance, because the board never developed a structural process for stress-testing what management was telling them. The CMO becomes the single point of judgment for every clinical decision; the CSO becomes the single point of judgment for every scientific question. This is not delegation; it is abdication. The board's role is reduced to ratification.
The second is performance. The board, uncomfortable with deference, asks questions designed to demonstrate engagement rather than to elicit information. Directors ask about details they can pattern-match on without actually understanding the substance — sample sizes, p-values, primary endpoints — and management responds with answers calibrated to satisfy without illuminating. Everyone leaves the meeting feeling like a real discussion took place. The asymmetry is unchanged. The board's documentary record looks active; the actual oversight is no better than it would have been under pure deference.
The third is over-reliance on a single expert director. The board, recognizing the asymmetry, has recruited one director with deep clinical or scientific credibility — a former CMO, a senior academic, a physician with relevant experience — and that director becomes the de facto interpreter of all clinical and scientific matters for the rest of the board. The other directors stop trying to engage substantively because the expert director is there to do it for them. This produces a two-tier board: one director who is in the discussion and several who are present at it. It also creates significant concentration risk: if the expert director is wrong, has a blind spot, or has a conflict of interest, there is no second pair of eyes to catch it.
The fourth is excessive use of outside consultants. The board, recognizing that it cannot evaluate the science internally, hires outside scientific advisors, regulatory consultants, and clinical experts for every meaningful decision. This is expensive, slow, and undermines the management team in ways that have organizational costs. It also does not actually solve the asymmetry — the board is now dependent on the consultants instead of management, which is a different dependency but not a structurally better one.
None of these patterns is uniquely bad. Each is a reasonable response to a genuinely difficult condition. But each, taken as the primary mode of governance, produces predictable failure modes. The boards that handle the asymmetry well do something different.
What Actually Works
The governance disciplines that allow a board to function well despite the information asymmetry are not glamorous. They are a small number of structural commitments, applied consistently, that produce better outcomes over time without eliminating the underlying problem.
The first is composition. A clinical-stage biopharma board should have at least one director — ideally two — who can engage substantively at the scientific and clinical level. This is not a luxury; it is a basic precondition for the board doing its job. The qualifying expertise depends on the company's stage and therapeutic area: a board overseeing a Phase III oncology asset needs different expertise than a board overseeing a preclinical platform company. But the principle is constant. A board where no director can independently engage with the science is a board that has structurally accepted that its scientific oversight will be limited to ratification.
The second is the discipline of asking structural questions even when the board cannot evaluate the substantive ones. There are three questions that work regardless of how technical the matter is. What would have to be true for this conclusion to be wrong? Who else has looked at this, and what did they say? What is the strongest case the most skeptical reasonable observer would make against this position? None of these questions requires the director asking it to be able to evaluate the underlying science. All of them surface the kind of information that the board needs to assess whether management has stress-tested its own thinking.
The third is the use of scientific advisory boards as actual governance infrastructure rather than decoration. Many small biopharma companies maintain scientific advisory boards that meet annually, receive an honorarium, and produce no meaningful oversight. The companies that get more value from their SABs treat them differently — using them between formal meetings, asking them to review specific protocols or data packages, and reporting their feedback to the board substantively rather than as a checkbox. The board's relationship to the SAB matters here: the SAB's reports should come to the board, not be filtered through management.
The fourth is the discipline of separating two questions that get conflated. The first question is "what does this mean," and it is appropriately addressed to management. The second question is "what could this also mean," and it has to be addressed to someone other than management. This is the most consistent failure mode in how boards engage with clinical data. When the CMO presents a trial result and explains what it means, the directors who only ask follow-up questions of the CMO are operating in a single-source information environment. The directors who additionally seek out a second view — from a scientific advisor, from a director with relevant background, from an outside consultant brought in selectively — are operating in something closer to a genuine governance environment.
The fifth is the discipline of making management's interpretation falsifiable. Before a trial reads out, the board should know — from management, on the record — what would constitute success, what would constitute failure, and what range of intermediate outcomes would justify what range of follow-on decisions. This is harder than it sounds. Management often resists pre-committing because they want to retain interpretive flexibility for the post-readout discussion. The boards that establish this discipline early, before any trial is anywhere near readout, produce a much cleaner basis for evaluating results when they arrive. The boards that do not are inviting the most common form of management bias: the post-hoc rationalization of whatever the data showed.
The sixth is the use of outside expertise selectively and structurally. Not for every decision — which is too expensive and too undermining of management — but for specific moments. A pre-trial protocol review by an outside expert. A pre-Advisory Committee briefing from a regulatory consultant who has been through similar situations. An independent statistical review of a complex interim analysis. The discipline is to know which decisions warrant outside input and to engage it before the decision is made, not after.
These six disciplines do not eliminate the information asymmetry. They cannot. What they do is establish the structural conditions under which the board's judgment is the product of more than just management's interpretation of the data. They produce a governance environment where the directors, while still dependent on management for most technical content, are dependent on management plus a defined set of independent checks that surface the questions management would not have surfaced on its own.
The Deeper Principle
The information asymmetry problem is not, ultimately, a problem to be solved. It is a condition to be governed under. The chemistry will not get easier. The trial designs will not get simpler. The regulatory mechanics will not become more transparent. A board that takes its responsibilities seriously has to accept, at a fundamental level, that it will be making consequential decisions on the basis of information it cannot fully evaluate.
What changes, when a board engages with the asymmetry well, is the structure within which those decisions get made. The board still cannot verify, in real time, whether the CMO's interpretation of the latest interim data is correct. But the board has built — over years, deliberately, through composition and process — a governance environment in which alternative interpretations get surfaced, in which management's claims are stress-tested, in which the worst-case readings get heard alongside the central case, and in which the directors have at least one credible internal voice that can engage substantively with the technical content.
This is the most realistic version of biopharma board oversight. It is not the version where directors verify everything they are told. It is the version where directors have built the structural protections that mean they do not need to.
The boards that fail in biopharma rarely fail because they had bad information. They fail because they had a single source of information — usually management — and no structural mechanism for testing it. The boards that succeed are not the ones with the smartest individual directors. They are the ones that have organized themselves to compensate, structurally, for a condition that no individual director can overcome.
Acknowledging the information asymmetry explicitly is the precondition for doing this well. The boards that pretend they can evaluate the substance, or pretend they do not need to, are the boards that will eventually be surprised. The boards that name the problem and design around it are the boards that, over time, build the kind of oversight that biopharma governance actually requires.
Lawrence Fine is CEO of AGCP Farmacêuticos and has direct biopharma board experience through Phase II clinical trials and successful exits.